Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
AssigneeDicerna Pharmaceuticals, Inc.
InventorBob D. Brown
Life of this patent
Estimating the term…
Abstract
This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures.
Claims26
An isolated double stranded nucleic acid (dsNA) comprising first and second nucleic acid strands and a duplex region of at least 25 base pairs, wherein each of said first and second nucleic acid strands comprises RNA and has a length which is at least 25 and at most 35 nucleotides, wherein said second oligonucleotide strand is perfectly complementary to SEQ ID NO:
- 4909 along at least 21 nucleotides of said second oligonucleotide strand length to reduce KRAS target gene expression when said double stranded nucleic acid is introduced into a mammalian cell.
A composition possessing KRAS inhibitory activity consisting essentially of an isolated double stranded ribonucleic acid (dsNA) comprising first and second nucleic acid strands and a duplex region of at least 25 base pairs, wherein said second strand of said dsNA comprises 1-5 single-stranded nucleotides at its 3′ terminus, wherein said second oligonucleotide strand is perfectly complementary to SEQ ID NO:
- 4909 along at least 21 nucleotides of said second oligonucleotide strand length and said double stranded nucleic acid reduces KRAS target gene expression when said double stranded nucleic acid is introduced into a mammalian cell.
Dependencies are inferred from the claim text.